Medexus Pharmaceuticals (MDP.T) has been a name synonymous with stellar growth and innovation. With its stock price climbing from $0.90 to $2.90 in a short period, it has captured the attention of investors and financial experts. Chris Parry from Equity Guru recently shed light on this thrilling success story. Here’s what he had to say:

From Humble Beginnings to Sky-High Potential

Medexus, with its ticker symbol MDP, has undergone remarkable transformations. Just a few months ago, the stock was at $0.90. It then skyrocketed to $2.10 and $2.90, boasting a revenue of $120 million US yearly. According to Parry, the stock, with its $58 million Canadian market cap, is still massively undervalued and should be at least a $5 stock.

The FDA, Treosulfan, and the Road Ahead

The road to success hasn’t been smooth for Medexus. The process they’ve been going through with the FDA for a drug called treosulfan has been cumbersome, leading to considerable fluctuations in the stock’s value. But as Chris puts it, they’ve reached a point where “they don’t even need treosulfan.” Medexus’s existing products are more than sufficient to sustain and increase their revenue.

Battling Debt and Winning the Game

Medexus faced a daunting challenge of debt coming due, which led to market speculations and fear. Chris vividly narrates how they tackled the issue head-on by negotiating with banks, securing the funds, and even reducing their interest rate. They turned a problem into a triumph, displaying strong financial stability.

Chris Parry’s Personal Insights and Investment Strategy

Chris’s passion for Medexus is palpable in his detailed analysis. He talks about buying in at ninety cents, holding, and making strategic sales to maximize profit without being greedy. He believes that the stock’s value should rise to about $3 or $3.50 before settling at a new floor.

A Symbol of Resilience

Every single interaction with Medexus CEO, Ken d’Entremont, and the company has only strengthened Chris’s belief in their vision. The growth, revenue generation, and risk mitigation strategies were always clear. The entire journey, from an underappreciated stock to its current hockey stick growth, epitomizes a success story.

A Win for All

Medexus’s growth is an inspiring tale for anyone looking to understand the intricacies of the stock market and business growth. It’s a real upside for those who believed in the stock and decided to take a gamble. Chris’s insightful analysis proves that with in-depth understanding, patience, and a clear vision, success is achievable. His ending words, “We were right. They were right. And anyone who bought in along the way, congratulations. Good job,” resonates with anyone who has followed the Medexus story closely.